Episode 5: Managing NAFLD and NASH

Overview

In this podcast, AGA Institute’s NASH: Take Action! Steering Committee members talk to global leaders in gastroenterology, hepatology, endocrinology and primary care about the real-world, practical implications of screening, diagnosing and managing people with NAFLD and NASH. In this episode we’re talking about managing NAFLD and NASH.

Learning Objectives

By the end of this podcast, listeners will be able to:

Understand the importance of managing co-morbidities
Discuss current and emerging treatments for NAFLD and NASH
Discuss limitations in current data for the management of NAFLD and NASH

Key Takeaways

Reducing excess weight (whether via lifestyle modifications, liver-directed pharmacotherapy, and/or bariatric surgery) is the cornerstone of therapy for both liver disease progression and its cardiometabolic complications.
Statin therapy is generally safe and efficacious in reducing risk of cardiovascular complications in patients with NAFLD and NASH.

CME

To claim credit, visit AGA University. You will need to create a free account to log in and claim your credit.

This activity is accredited through Sep. 30, 2022.

The AGA Institute is accredited by the ACCME to provide continuing medical education for physicians. The AGA Institute designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 24 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

Credits

Hosts: Fasiha Kanwal, MD, Baylor College of Medicine; Kenneth Cusi, MD, University of Florida; Jay Shubrook, DO, Touro University

Guest: Robert H. Eckel, MD, University of Colorado

Created by: Knighten Health, LLC

Produced and edited by: Nick Jaworksi

Cover art: THOR Design Studio

Disclosures

Fasiha Kanwal discloses no conflicts.

Kenneth Cusi has received research support for the University of Florida as principal investigator from Cirius, Echosens, Inventiva, Novo Nordisk, Poxel and Zydus and is a consultant for Allergan, Arrowhead, Astra-Zeneca, Axcella, BMS, Boehringer Ingelheim, Coherus, Eli Lilly, Fractyl, Hanmi, Genentech, Gilead, HighTide, Inventiva, Intercept, Ionis, Janssen, Pfizer, Poxel, Prosciento, Madrigal, and Novo Nordisk.

Jay H. Shubrook has served as an advisor to Sanofi, Eli Lilly, Novo Nordisk, Bayer, and MannKind.

Robert H. Eckel has served on advisory boards for Novo Nordisk, Provention Bio, Kaleido, and LOWA, and a scientific advisory committee for PROMINENT (CVOT).

Sponsor

American Gastroenterological Association

Funding

This podcast series was supported by an independent medical education grant from Novo Nordisk Inc.